Alefacept + tacrolimus + basiliximab + mycophenolate mofetil + Corticosteroids
Phase 2Completed 1 views this week 0 watching💤 Quiet
Interest: 35/100
35
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Kidney Transplantation
Conditions
Kidney Transplantation
Trial Timeline
Feb 1, 2008 → Feb 1, 2011
NCT ID
NCT00543569About Alefacept + tacrolimus + basiliximab + mycophenolate mofetil + Corticosteroids
Alefacept + tacrolimus + basiliximab + mycophenolate mofetil + Corticosteroids is a phase 2 stage product being developed by Astellas Pharma for Kidney Transplantation. The current trial status is completed. This product is registered under clinical trial identifier NCT00543569. Target conditions include Kidney Transplantation.
What happened to similar drugs?
20 of 20 similar drugs in Kidney Transplantation were approved
Approved (20) Terminated (1) Active (0)
✅basiliximab + rabbit anti-thymocyte globulin + tacrolimus + alemtuzumab + mycophenolate mofetil + steroidsAstellas PharmaApproved
Hype Score Breakdown
Clinical
12
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00543569 | Phase 2 | Completed |
Competing Products
20 competing products in Kidney Transplantation